

Case Study: Systemic Evaluation of Vial Container Closure System Suitability at Frozen Conditions

- Coralie Richard, Eli Lilly and Company
- With Significant Contribution from Peter Sargent, Eli Lilly and Company

Agenda

- Background
- Risk Assessment
 - Suitability Hazards
- Phase based strategy
 - Screening Assessment
 - Development
 - Scale Up
- Takeaways

Background

Evolving needs for deep frozen storage

- Cell/gene therapies
- Vaccines

Opportunities for extended expiry

- Increased protein stability for biologics
- Establish shelf-life with limited stability knowledge

COVID-19 VACCINE STORAGE REQUIREMENTS



PRIOR TO VIAL USE:

- Prior to thawing, store in an ultra-cold freezer between -80°C to -60°C
- Once thawed, the vial can be stored undiluted in two ways:
 - Up to 5 days in a refrigerator
 - No more than 30 minutes at room temperature

Once Vial is First Used:

- Store between 2°C and 25°C for no more than 6 hours.

DO NOT REFREEZE

PRIOR TO VIAL USE:

- Prior to puncturing the vial, the product can be stored in three ways:
 - Frozen between -25°C and -15°C (Recommended unless immediate use is necessary)
 - Refrigerated between 2°C and 8°C for up to 30 days
 - Unrefrigerated for up to 12 hours

Once Vial is First Used:

- Store between 2°C and 25°C for no more than 6 hours.

DO NOT REFREEZE

PRIOR TO VIAL USE:

- The product can be stored in two ways:
 - Refrigerated between 2°C and 8°C for no more than 3 months
 - Unrefrigerated between 9°C and 25°C for up to 12 hours.

Once Vial is First Used:

- The product can be stored in two ways:
 - Refrigerated between 2°C and 8°C for up to 6 hours
 - At room temperature for up to 2 hours.

DO NOT REFREEZE

Risk Assessment: Suitability Hazards

Protection Risk

- Loss of elastomer elasticity below Tg
 - Sealing failures are temporary


- Increased risk for breakage due to liquid expansion

Performance Risk

- Mechanical/thermal stresses of shipping
- Thermal stresses of processing streams
- In-use performance after thaw

Safety & Compatibility

- Frozen conditions favorable for DP stability and E/L



(A) is an unstressed polymer; (B) is the same polymer under stress. When the stress is removed, it will return to the A configuration. (The dots represent cross-links)

Wikipedia, Elastomer

Risk Assessment: Phased Approach

Stage Description	Screen	Confirm	Develop	Scale Up
Activities	<ul style="list-style-type: none"> Form/Fit Concerns Finite Element Analysis 	<ul style="list-style-type: none"> In-Use conditions CT X-Ray Inherent Leak (HeLD) 	<ul style="list-style-type: none"> Head Space Analysis Stability Shipping Hazards 	<ul style="list-style-type: none"> Process Mapping Structural Integrity
Phase	<p>Ph 1/2</p> <p>Ph 3/ Primary Stability</p>			
Focus	<p>Design and Systemic Risk with Focus on Patient Safety</p> <p>Process Suitability and Business Risk</p>			

- *Right size the approach*
- *Gate transitions between phases*
- *Expand the system boundaries*

Risk Assessment: Phased Approach

Screen for Form/Fit issues at 'standard' conditions

- Machinability studies
- Stacked Tolerance Analysis

Confirm & Develop frozen use conditions

- Identify lower temp. bound in storage and shipping
- Understand supply chain risk points
 - Impact of Shipping Hazards
 - Temperature transitions

Apply a world view in the scale up process

- Transition to outcomes thinking
- Propagation of stresses means propagation of risk

Screening: CAE

Characterize component Materials of Construction as inputs to computer aided engineering and modelling

Vials


Assumed to be a rigid body

Elastomer

- Viscoelastic characterization $> T_g$
- Elasto-plastic characterization $< T_g$

Seals



- T_g
- CTE
- Poisson



Screening: CAE

Evaluate contact pressure

- Include lower temperature bound
- Consider shelf life




	Contact pressure (MPa)	Contact force (N)
Maximum	1	25.7
Relaxed	0.864	22.2

Development: CT Imaging



Confirm modeling assumptions via CT x-ray

- Look for variance between normal conditions and frozen

Pre-Freeze




Frozen



Development: CCI

Inherent Leak Rate

- Conduct as guided by USP <1207>
- Conduct at temperature via HELD
- Focused on design risk



Headspace Analysis

- Allows for CCI evaluation at in-use conditions
 - Incorporates temperature
 - Apply known shipping & shelf life constraints



- -78 °C, headspace underpressure
- Stopper loose elasticity, interface gaps
- CO₂ in headspace
- Warm up, stopper reseals
- CO₂ trapped



Development: Seal Quality Test

Developing a Readily Available Primary Packaging System for Use in an Ultra-Cold Chain for COVID19 Vaccine Global Distribution – Using a Scientific Approach

Co-presenters:
Michael Edey, Pfizer
Derek Duncan, Lighthouse Instruments

2021 PDA Parenteral Packaging Conference

Combination C: RSF and CO₂ ingress results



- Vial-stopper combination C: 1 week storage at -80 C in a CO₂ rich environment
- 73 of 80 samples (*lowest capping setting*) 38 of 80 samples (*mid low capping setting*), and 1 of 80 samples (*high capping setting*) measured increased CO₂ levels, indicating loss of CCI during cold storage

Scale Up: Approach

Shift the focus from systemic to residual risk

- Transition from design → process

- Emphasize control strategy development
 - Consider incoming, filling, and transit
 - Incorporate 2^o packaging?

- Employ statistical powering

Scale Up: Structural Integrity

Hazards

- Liquid expansion at phase change
- Freeze/thaw at shipping nodes
- Mechanical stresses
 - Vibration and Drop during shipment
 - Glass to glass contact at filling


DOE considerations

- Storage Temperature/orientation
- Shipping conditions: temperature, method, e.g. dry ice
- Fill volume, CCS size
- Best outputs (RSF, CCI)

Scale Up: Process Mapping

Process Mapping

- Understand temperature transitions
- Build in high-volume production hazards
- Adopt a statistical approach and foundation



Takeaways

- Risk Assessment Strategy
 - Use a right sized, phase approach
- Screen
 - Design and Systemic Concerns
 - Is it possible?
- Confirm and develop
 - Establish baseline suitability
 - Focus on the destination
- Scale up
 - Expand the system boundary for risk
 - Focus on the journey

Acknowledgments

- Craig Kemp
- Craig Goldhammer
- Lin Li
- Michael Foubert
- Vijay Sharma
- Lei Li
- Mark Beidelschies
- Michael Boquet
- David Lyngholm